Project description
Personalised treatment for bone fracture non-union
Non-union of bone after fracture occurs in some patients and there is currently no approved drug or other treatment that is effective. It results in significant challenges, increased risks and even death to patients and it costs healthcare systems billions of euros annually. The EIC-funded OSTEOforUNION project aims to develop and commercialise OSTEOGROW-C, a globally patented drug for bone regeneration developed by the Croatian SME Genera Research. OSTEOGROW-C, based on recombinant human morphogenetic protein 6, transforms patients’ blood into bone. Surgeons can use OSTEOGROW-C to prepare a personalised implant in the operating room during surgery, eliminating the need for bone harvesting which is currently required to prepare conventional therapies.
Objective
Bone fracture nonunion (FNU) is one of the leading unmet orthopaedic clinical needs, resulting in billions of healthcare costs annually without any drug approved by regulatory agencies for this debilitating indication. Due to considerable shortcomings of the current best practices in treating bone FNUs, patients are facing increased risks and morbidity. The market has available only bone substitutes and enhancers with limited clinical efficiency, highlighting an essential need for more effective therapies. Genera Research is on its way to filling the gap with its globally patented OSTEOGROW-C product: a novel biological drug transforming patients blood into bone.
The proposed OSTEOforUNION project aims to develop and commercialize OSTEOGROW-C, an innovative drug for bone regeneration. OSTEOGROW-C is a novel treatment option for bone FNUs, an implant composed of an active substance - recombinant human bone morphogenetic protein 6 (rhBMP6) incorporated in an autologous blood coagulum (ABC) where tricalcium phosphate (TCP) ceramics is added as a compression resistant matrix (CRM). This combination forms a personalized implant that catalyzes bone growth at the implantation site. It is easily prepared in the operating room from the patient's blood without the need for a painful bone harvesting procedure, as in current treatment practices, with associated complications and morbidities (donor site pain, infection, nerve injuries, blood loss or iliac wing fracture etc.) and related additional healthcare costs.
OSTEOGROW-C targets the global FNU market, which serves 6M patients yearly. Key overlapping markets are Fracture Fixation, Orthobiologics, Bone Grafts, and BMP. OSTEOGROW-C's unique stance promises to revolutionize the FNU market. The initial market entry will concentrate on the markets in the EU with 180.000 diagnosed long bone FNUs in Europe annually. Simultaneously, OSTEOGROW-C will be launched in the US, addressing more than 120.000 bone FNUs.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences medical biotechnology implants
- engineering and technology materials engineering ceramics
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC-ACC - HORIZON EIC Accelerator
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
10436 Kalinovica
Croatia
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.